MAZINDOL - Generic Drug Details

✉ Email this page to a colleague

What are the generic sources for mazindol and what is the scope of patent protection?

Mazindol is the generic ingredient in two branded drugs marketed by Wyeth Ayerst and Novartis, and is included in two NDAs. Additional information is available in the individual branded drug profile pages.

Summary for MAZINDOL

US Patents:	0
Tradenames:	2
Applicants:	2
NDAs:	2
Raw Ingredient (Bulk) Api Vendors:	48
Clinical Trials:	5
Patent Applications:	6,528
DailyMed Link:	MAZINDOL at DailyMed

Recent Clinical Trials for MAZINDOL

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
NLS Pharmaceutics	Phase 3
NLS Pharma Inc.	Phase 2
NLS Pharmaceutics	Phase 2

See all MAZINDOL clinical trials

Medical Subject Heading (MeSH) Categories for MAZINDOL

Adrenergic Uptake Inhibitors
Central Nervous System Stimulants
Dopamine Uptake Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for MAZINDOL

A08AA	Centrally acting antiobesity products
A08A	ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS
A08	ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS
A	Alimentary tract and metabolism

US Patents and Regulatory Information for MAZINDOL

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	SANOREX	mazindol	TABLET;ORAL	017247-002	Approved Prior to Jan 1, 1982		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Wyeth Ayerst	MAZANOR	mazindol	TABLET;ORAL	017980-001	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Novartis	SANOREX	mazindol	TABLET;ORAL	017247-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Wyeth Ayerst	MAZANOR	mazindol	TABLET;ORAL	017980-002	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for MAZINDOL

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Wyeth Ayerst	MAZANOR	mazindol	TABLET;ORAL	017980-002	Approved Prior to Jan 1, 1982	⤷ Sign Up	⤷ Sign Up
Novartis	SANOREX	mazindol	TABLET;ORAL	017247-002	Approved Prior to Jan 1, 1982	⤷ Sign Up	⤷ Sign Up
Novartis	SANOREX	mazindol	TABLET;ORAL	017247-001	Approved Prior to Jan 1, 1982	⤷ Sign Up	⤷ Sign Up
Wyeth Ayerst	MAZANOR	mazindol	TABLET;ORAL	017980-001	Approved Prior to Jan 1, 1982	⤷ Sign Up	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.